Current Opinion in Lipidology was launched in 1990. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of lipidology is divided into six sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editor and Section Editors for this issue.
Scott M. Grundy, MD, PhD, is Director of the Center for Human Nutrition, Chairman of the Department of Clinical Nutrition, and Director of the Clinical and Translational Research Center at the University of Texas (UT) Southwestern Medical Center at Dallas, Texas, and Chief of the Metabolic Unit, Veterans Affairs Medical Center, also in Dallas. In recognition of his academic endeavors, he has earned the title of Distinguished Professor of Internal Medicine at the UT Southwestern Medical School in Dallas. Previous academic appointments include the University of California, San Diego; the National Institutes of Health (NIH) Phoenix Clinical Research Unit; the Rockefeller University in New York City; and Baylor College of Medicine in Houston, Texas. Dr Grundy received his medical degree from Baylor College of Medicine and his doctorate from the Rockefeller University.
Dr Grundy's research interests primarily focus on nutrition and cholesterol and lipoprotein metabolism. Notable research achievements include developing methods for measuring cholesterol balance and biliary lipid secretion in humans; identifying the metabolic causes of cholesterol gallstones; defining effects of saturated and unsaturated fats, especially monounsaturated fatty acids, on cholesterol and lipoprotein metabolism; uncovering genetic defects underlying elevated blood cholesterol and other lipid disorders; and identifying metabolic defects of elevated blood cholesterol, high triglycerides, and low HDL (the good cholesterol), and defining mechanisms of action of several lipid-lowering drugs, notably fibrates and HMG CoA reductase inhibitors (statins). Recently, Dr Grundy's research has focused on the metabolic syndrome. Complementing his research endeavors, he writes for the general medical literature, and has published more than 350 original papers and numerous solicited articles and chapters.
Among the many honors bestowed upon him in the course of his career, Dr Grundy received The Award of Merit, the Distinguished Scientist Award, and the Gold Heart Award from the American Heart Association (AHA), the Bristol-Myers Squibb Award for Distinguished Achievement in Nutrition Research, and the American Society for Clinical Nutrition's E. V. McCollum Award. He was also the recipient of the Roger J. Williams Award in Preventive Nutrition and was awarded an honorary degree in medicine from the University of Helsinki in Finland. Additionally, he holds the distinction of having presented the Lydia J. Roberts Memorial Lecture in Chicago in 1988, the AHA George Lyman Duff Lecture, and the AHA Robert I. Levy Lecture.
Dr Grundy has served in various capacities on a number of AHA committees, including chairmanship of the Nutrition Committee, the Council of Arteriosclerosis, Thrombosis, and Vascular Biology, the Council on Nutrition, Physical Activity, and Metabolism, the Task Force on Risk Reduction and Task Force on Cholesterol. He chaired the Adult Treatment Panels II and III of the National Cholesterol Education Program (NCEP) and is a member of the American Society for Clinical Investigation, the American Association of Physicians, and the National Academy of Sciences (Institute of Medicine).
Frank M. Sacks
Dr Sacks is Professor of Cardiovascular Disease Prevention, Department of Nutrition, Harvard School of Public Health, USA. He is also Professor of Medicine at Harvard Medical School, USA, and a senior attending physician at Brigham and Women's Hospital where he has had a specialty clinic in hyperlipidemia with the cardiovascular division. He is involved in research and public policy in nutrition, cholesterol disorders, hypertension, and cardiovascular disease.
His research program is a combination of laboratory research on human lipoprotein metabolism, and clinical trials in nutrition and cardiovascular disease. Dr Sacks was Chair of the Design Committee of the DASH study where the DASH diet was designed, and Chair of the Steering Committee for the DASH-Sodium trial. Dr Sacks was Co-Chair of the OmniHeart Trial, a multicenter feeding trial that found that a variation of the DASH diet that is higher in protein or unsaturated fat diets further improved blood pressure and lipid risk factors compared to the lower fat DASH-type diet.
Dr Sacks is active in national and international committees and conferences in dietary and drug treatments of dyslipidemia, and nutrition and health guidelines. He is Chair of the American Heart Association Nutrition Committee and was a member of the National Cholesterol Education Program Adult Treatment Panel IV, the NIH advisory group that is developing new guidelines for treatment of dyslipidemia. He was a member of the Hypertriglyceridemia Guidelines Committee of the Endocrine Society. He is a member of the Lifestyle Working Group of the National Heart Lung and Blood Institute Clinical Guidelines for Reducing Cardiovascular Disease.
Dr Sacks received the 2011 Research Achievement Award of the American Heart Association and has published 175 original research articles and 72 reviews, editorials, and letters.
Lawrence J. Appel
Dr Lawrence Appel is Director of the Welch Center for Prevention, Epidemiology and Clinical Research, a joint program of the Johns Hopkins School of Medicine, USA and the Bloomberg School of Public Health, USA. Dr Appel is a Professor of Medicine with joint appointments in Epidemiology and International Health. The focus of Dr Appel's investigative career is the conduct of clinical, epidemiologic and translational research pertaining to the prevention of hypertension, cardiovascular disease, and kidney disease.
To this end, he leads three complementary research programs:
1. controlled feeding trials that identify optimal diet (e.g. DASH, DASH-Sodium, OmniHeart, OmniCarb)
2. behavioral intervention trials that test novel strategies to accomplish lifestyle modification, often focused on obesity (e.g. PREMIER, Weight Loss Maintenance, and POWER)
3. trials and observational studies to understand risk factors for chronic kidney disease progression and its complications (e.g. AASK and CRIC)
He has a keen interest in research methods and has conducted a diverse array of studies, including cohort studies, clinical trials, and meta-analyses. A particularly notable feature of this research is the focus on chronic conditions and diseases that disproportionately afflict minorities and on interventions that have the potential to substantially reduce racial disparities.
Dr Appel has been actively involved in health care policy. He was a member of the 2005 and 2010 U.S. Dietary Guidelines Scientific Advisory Committees. For the American Heart Association, he has been a member of its Nutrition Committee for over 10 years and a past chair. He has also served on several Institute of Medicine Committees and chaired the committee that set dietary reference intakes for sodium, potassium and water. He has served on numerous advisory committees for the National Institutes of Health.